tbuckley/cabot-search huggingface dataset:
A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.
Authors: Richard M. Stone, Barry Moser, Philip Schulman, Robert C. Barrier, Jonathan E. Kolitz, Steven L. Allen, Wendy Stock, Ilene A. Galinsky, Hanna Khoury, Richard A. Larson
Journal: Blood (2004)
A PI3K/AKT Scaffolding Protein, IQ Motif–Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis
Authors: Tao Wei, Suyong Choi, Darya Buehler, Richard A. Anderson, Paul F. Lambert
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Head and neck cancer (HNC) is the sixth most common cancer worldwide with a 5-year survival rate of less than 50%. The PI3K/AKT/mTOR signaling pathway is frequently implicated in HNC. Recently, IQ motif–containing GTPase-activating protein 1 (IQGAP1) was discovered to scaffold the PI3K/AKT signaling pathway. IQGAP1 gene expression is increased in HNC, raising the hypothesis that IQGAP1 contributes to HNC. Experimental Design: We performed a combination of in vitro studies using human cancer cell lines treated with a cell-permeable peptide that interferes with IQGAP1′s ability to bind to PI3K, and in vivo studies utilizing mice genetically knocked out for the Iqgap1 (Iqgap1−/−). In vivo EGF stimulation assays were used to evaluate PI3K signaling. To study the role of IQGAP1 in HNC, we used a well-validated mouse model that drives HNC via a synthetic oral carcinogen, 4-nitroquinoline 1-oxide (4NQO). Results: IQGAP1 is necessary for efficient PI3K signaling in vitro and in vivo. Disruption of IQGAP1-scaffolded PI3K/AKT signaling reduced HNC cell survival. Iqgap1−/− mice had significantly lower cancer incidences, lesser disease severity, and fewer cancer foci. IQGAP1 protein levels were increased in HNC arising in Iqgap1+/+ mice. The level of PI3K signaling in 4NQO-induced HNC arising in Iqgap1−/− mice was significantly reduced, consistent with the hypothesis that IQGAP1 contributes to HNC at least partly through PI3K signaling. High IQGAP1 expression correlated with reduced survival, and high pS6 levels correlated with high IQGAP1 levels in patients with HNC. Conclusions: These data demonstrate that IQGAP1 contributes to head and neck carcinogenesis.
Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer
Authors: Miguel Quintela-Fandino, Serafín Morales, Alfonso Cortés-Salgado, Luis Manso, Juan V. Apala, Manuel Muñoz, Ariadna Gasol Cudos, Joel Salla Fortuny, María Gion, Antonio Lopez-Alonso, Javier Cortés, Juan Guerra, Diego Malón, Eduardo Caleiras, Francisca Mulero, Silvana Mouron
Journal: Clinical Cancer Research (2019)

We previously demonstrated that mitochondrial inhibitors' efficacy was restricted to a metabolic context in which mitochondrial respiration was the predominant energy source, a situation achievable by inducing vascular normalization/hypoxia correction with antiangiogenics. Vascular normalization can be tracked with 2[18F]fluoro-2-deoxy-d-glucose (FDG)-PET. We tested the efficacy of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early breast cancer.Treatment-naïve HER2-negative patients with T > 1 cm (any N) underwent a breast-centered 18F-fluorodeoxyglucose (FDG)-PET (day 1) and received a single dose of bevacizumab (15 mg/kg), followed by a second FDG-PET (day 8). Patients were then randomized (1:1) to Arm A (ME-344 10 mg/kg intravenous on days 8, 15, and 21) or Arm B (placebo). Tumors were biopsied on days 0 and 29. Succinate dehydrogenase enzyme histochemistry (SDH-EHC), confocal microscopy of vessel architecture, and HIF1α staining were performed in pre- and posttreatment biopsies to assess the pharmacodynamics, vessel normalization, and tissue re-oxygenation by bevacizumab, respectively.ME-344 displayed significant biological activity versus placebo: compared with a 186% increase in Arm B, Ki67 decreased by 23.4% from days 0 to 28 in Arm A (P < 0.001) (N = 42 patients). FDG-PET predicted vascular normalization in about one-third of the patients in each arm, which was confirmed using confocal microscopy and HIF1α staining. In the subgroup with vascular normalization, ME-344 induced a Ki67 decrease of 33.4% (placebo: 11.8 increase). SDH-EHC suggested on-target effects of ME-344.ME-344 has significant biological antitumor activity in HER2-negative breast cancer, particularly after induction of vascular normalization and tissue reoxygenation with bevacizumab.
Single centre, retrospective review of gamma-knife stereotactic radiosurgery and other therapies on prevalence of seizures in patients with brain metastases
Authors: James De Boisanger, Katherine Mackay, Cornel Tancu, Naomi Fersht, Neil Kitchen, Jeremy Rees
Journal: Neuro-Oncology (2019)

Abstract Background An increasing number of patients with brain metastases (BM) are having stereotactic radiosurgery (SRS), but it is not known whether this causes epilepsy. Methods We carried out a retrospective review of patients surviving one-year post gamma-knife SRS at the National Hospital for Neurology and Neurosurgery (NHNN) between February 2012 and April 2017. Data on seizures during the pre- and post-SRS periods were collected along with information about the primary tumour, metastasis location and previous treatments, including whole brain radiotherapy (WBRT) and surgery. Results 61 patients were treated with SRS. 6 patients had incomplete records and were excluded. Of the remaining 55, 21 had a seizure at some point. 4 had seizures both pre- and post-SRS, 7 had seizures pre-SRS but not post and 10 patients had de-novo seizures post-SRS. 34 did not have a documented seizure at any point. Of the 14 patients who had seizures post-SRS, 4 also had both WBRT and surgery, 2 had WBRT and 4 had surgery. 100% (4/4) who had WBRT, surgery and SRS went on to have a seizure. Seizures occurred in 11/25 patients who had previous surgery and 7/11 who had previous WBRT. The primary tumour and metastasis location had no obvious impact on seizure incidence. Conclusions The incidence of new seizures post-SRS is low (18%). Previous surgery and/or WBRT may increase seizure incidence post-SRS. The data is currently being reviewed for effect of tumour/ treatment volume, dose delivered, presence of significant oedema and radionecrosis. A larger prospective study is also underway.
Older Patients with AML Undergoing Matched Related Allogeneic Transplantation Have Significantly Older Donors but Equivalent Survival as Patients Receiving Unrelated Donor Transplants
Authors: Brian T. Hill, Lisa Rybicki, Brian J. Bolwell, Robert Dean, Brad Pohlman, Shawnda Tench, Ronald Sobecks, Steven Andresen, Edward A. Copelan, Matt Kalaycio
Journal: Blood (2010)
Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.
Authors: Enrique M. Ocio, Constantine Mitsiades, M. Victoria Mateos, Patricia Maiso, Faustino Mollinedo, Mercedes Garayoa, Consuelo Gajate, Joan Blade, Felipe Prosper, Juan José Lahuerta, Nicholas Mitsiades, Ciaran J. McMullan, Nikhil C. Munshi, Teru Hideshima, Dharminder Chauhan, Carmen Cuevas, Pablo Avilés, Glynn Faircloth, Paul G. Richardson, Atanasio Pandiella, Kenneth C. Anderson, J.F. San Miguel
Journal: Blood (2007)
Autoantibodies Directed Against Moesin C471-577/N1-297 Are Novel and Specific Biomarkers of Immune Thrombocytopenic Purpura (ITP),
Authors: Yue Zhang, Hua Mao, Aimin Zhao, Feng Du, Xiaofang Liu, Shou Zhinan, Hongbin Sun, Chengxiu Gao, Yongjun Han, Weina Situ, Lei Sheng, Jie Qian, Yang Jian, Yong Xu, Jia Wei, Benjamin Bonavida, Haiming Chen
Journal: Blood (2011)
Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM).
Authors: James R. Berenson, Ralph Vincent V. Boccia, Mohamad A. Hussein, Andrew Belch, Lawrence Boise, Brian Schwartz, Robert Peter Gale, Steven M. Kornblau
Journal: Blood (2006)
Cord Blood CD34+ Stem Cell Sialyl Lewis X Levels and E-Selectin Binding Are Predictive Of Engraftment In Mice: Functional Separation Of Stemness and Homing To Improve Engraftment
Authors: Patrick A Zweidler-McKay, Simon N Robinson, Michael W Thomas, JunJun Lu, Hong Yang, Richard E Champlin, Wendy D Schober, Paul J Simmons, Elizabeth J Shpall
Journal: Blood (2013)
Preliminary Results of Safety and PK of Telisotuzumab Vedotin (T) in Japanese Patients with Advanced Solid Tumors
Authors: Haruyasu Murakami, Kazushige Wakuda, Hirotsugu Kenmotsu, Akiko Todaka, Tomoya Yokota, Noboru Yamamoto, Toshio Shimizu, Akihiko Shimomura, Kan Yonemori, Christopher Ocampo, Apurvasena Parikh, Kazuteru Fukasawa, Ikiru Matsumoto, Koji Suzuki, Yutaka Fujiwara
Journal: Annals of Oncology (2019)
Pro-Survival Effects of TGF-β1 Are Associated with Molecular Signaling Changes of ERK, FLI-1, and CD44 in AML Cells
Authors: Yoko Tabe, Yasuhito Hatanaka, Peter P. Ruvolo, Takashi Miida, Steven M. Kornblau, Michael Andreeff, Marina Konopleva
Journal: Blood (2014)
Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting
Authors: Prajwal Chaitanya Boddu, Hagop M. Kantarjian, Abdul Rashid Shah, Gautam Borthakur, Srdan Verstovsek, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Farhad Ravandi, Nitin Jain, Ahmad Alhuraiji, Jan Burger, Steven M. Kornblau, Sara Emogene Dellasala, Sherry Pierce, Elias J. Jabbour, Jorge E. Cortes
Journal: Blood (2016)
AVA4746, an Orally Available, Clinical Grade Antagonist of Integrin Alpha 4, Sensitizes Pre-B Cell Acute Lymphoblastic Leukemia to Chemotherapy
Authors: Yongsheng Ruan, Eun Ji Gang, Hye-Na Kim, Chintan Parekh, Hisham Abdel-Azim, Deepa Bhojwani, Alan S. Wayne, Yong-Mi Kim
Journal: Blood (2016)
Anti-Proliferative Effect of Itraconazole On ALCL-Derived Cell Line
Authors: Naoka Okamura, Katsuya Ikuta, Hiroki Tanaka, Lynda Addo, Yasumichi Toki, Satoshi Ito, Motohiro Shindo, Kazuya Sato, Yoshihiro Torimoto, Yutaka Kohgo
Journal: Blood (2012)
Dual Inhibition of PI3K-Delta and Gamma By Duvelisib (IPI-145) Impairs CLL B- and T-Cell Migration, Survival and Proliferation in a Murine Xenograft Model Using Primary Chronic Lymphocytic Leukemia Cells
Authors: Shih-Shih Chen, Steven Ham, Kanti R. Rai, Karen McGovern, Jeffery L. Kutok, Nicholas Chiorazzi
Journal: Blood (2015)
Non-Myeloablative Haploidentical Transplantation of Unmanipulated, G-CSF Mobilized Peripheral Blood Stem Cells with High Dose Post-Transplant Cyclophosphamide: Fast Engraftment, No Evidence of Graft Rejection and Low Incidence of Graft-Versus-Host-Disease
Authors: Rocco Pastano, Giovanna Andreola, Federica Gigli, Angelo Gardellini, Mara Negri, Sarah Jayne Liptrott, Davide Radice, Giovanni Martinelli
Journal: Blood (2014)
Inhibition of Multiple Myeloma Cell Proliferation and Increase of Apoptosis through Regulation of the NF-κB and JNK Pathways by Silencing TRAF6 C-Domain mRNA.
Authors: Haiming Chen, Richard A. Campbell, Daocheng Zhu, Sonia Guangxu Li, Christine Pan James, Janice Santos, Cathy S. Wang, Benjamin Bonavida, James R. Berenson
Journal: Blood (2004)
Quantitative Proteomic Analysis Implicates An Altered B-Cell Differentiation State as a Mechanism Underlying GC-Resistance in An Acute Lymphoblastic Leukaemia (ALL) Cell Line Model.
Authors: Lindsay Nicholson, Caroline Evans, Elizabeth Matheson, Lynne Minto, Christopher Keilty, Andrew Hall, Christopher Redfern, Anthony Whetton, Julie Irving
Journal: Blood (2009)
Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells
Authors: Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, Peter Kufer, Roman Kischel, Gerhard Zugmaier, Thomas Köhnke, Torben Altmann, Stephanie Schneider, Michael Fiegl, Karsten Spiekermann, Angus M Sinclair, Kathryn J Newhall, Stanley R Frankel, Patrick Baeuerle, Wolfgang Hiddemann, Gert Riethmüller, Marion Subklewe
Journal: Blood (2014)
In Vitro and In Vivo Mouse Models of the Type 1 Von Willebrand Disease Mutations Y1584C and R1205H.
Authors: Cynthia M. Pruss, Kate Sponagle, Kimberly Laverty, Carol A. Hegadorn, Yvette Chirinian, Colleen Notley, Mia Golder, David Lillicrap
Journal: Blood (2009)
The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep
Authors: Ekapun Karoopongse, John Byon, Cecilia Yeung, H. Joachim Deeg, A. Mario Q. Marcondes
Journal: Blood (2013)
A Patient With Widespread Painful Purpura
Authors: Dayan J. Li, Alvaro C. Laga, Sotonye Imadojemu
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rare Variants Affecting the Fanconi Anaemia DNA Repair Genes Associate with Increased Risk for AML
Authors: Kyaw Ze Ya Maung, Paul Leo, Anna L Brown, Mahmoud A Bassal, Debora A. Casolari, Adam Ewing, Emma Duncan, Sarah C Bray, Evgeny Glazov, Luen Bik To, Russell Saal, Ian D Lewis, Devinder S Gill, Paula Marlton, James X Gray, Thomas J Gonda, Richard D'Andrea
Journal: Blood (2016)
Evaluation of Disease Progression in Arrhythmogenic Cardiomyopathy
Authors: Karim Taha, Thomas P. Mast, Maarten J. Cramer, Jeroen F. van der Heijden, Folkert W. Asselbergs, Pieter A. Doevendans, Arco J. Teske
Journal: JACC. Cardiovascular imaging (2019)
The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL).
Authors: Stefan Faderl, Alessandra Ferrajoli, William G. Wierda, Susan O’Brien, Farhad Ravandi-Kashani, Luis Fayad, Deborah Thomas, Hagop Kantarjian, Mary L. Browning RN, Michael J. Keating MB
Journal: Blood (2006)
Human Germinal Center-Associated Lymphoma (HGAL) Protein Expression Is Associated with Improved Failure-Free Survival in Brazilian Patients with Classical Hodgkin Lymphoma.
Authors: Denize Azambuja, Izidore Lossos, Irene Biasoli, José Carlos Morais, Luciana Britto, Adriana Scheliga, Wolmar Pulcheri, Yaso Natkunam, Nelson Spector
Journal: Blood (2009)
In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches
Authors: Aldo M. Roccaro, Antonio Sacco, Marco Ungari, Patricia Maiso, Salomon Manier, Phong Quang, Yosra Aljaway, Dirk Zboralski, Anna Kruschinski, Fabio Facchetti, Giuseppe Rossi, Irene M. Ghobrial
Journal: Blood (2012)
HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of "Pan-Leukemia"-Associated Antigens
Authors: Linus Backert, Daniel J. Kowalewski, Simon D. Walz, Heiko Schuster, Claudia Berlin, Mirle Schemionek, Tim H. Brümmendorf, Vladan Vucinic, Dietger Niederwieser, Lothar Kanz, Helmut R. Salih, Katja Weisel, Hans-Georg Rammensee, Stefan Stevanovic, Juliane S. Stickel
Journal: Blood (2016)
Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)
Authors: Umberto Vitolo, Marek Trněný, David Belada, Angelo M Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian W. Flinn, Xiaonan Hong, Won Seog Kim, Antonio Pinto, John M Burke, Yuankai Shi, Yoichi Tatsumi, Mikkel Oestergaard, Michael K Wenger, Günter Fingerle-Rowson, Olivier Catalani, Tina Nielsen, Maurizio Martelli, Laurie H Sehn
Journal: Blood (2016)
A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis
Authors: Christopher D. Barrett, Katharine Dobos, Michaela Liedtke, Mirela Tuzovic, Francois Haddad, Yukari Kobayashi, Richard Lafayette, Michael B. Fowler, Sally Arai, Stanley Schrier, Ronald M. Witteles
Journal: JACC Heart Failure (2019)
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Authors: Katherine E. Hutchinson, Susan E. Yost, Ching-Wei Chang, Radia Marie Johnson, Adrian R. Carr, Paul R. McAdam, Daniel L. Halligan, Chun-Chieh Chang, Daniel Schmolze, Jackson Liang, Yuan Yuan
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Emerging data suggest immune checkpoint inhibitors have reduced efficacy in heavily pretreated triple-negative breast cancers (TNBC), but underlying mechanisms are poorly understood. To better understand the phenotypic evolution of TNBCs, we studied the genomic and transcriptomic profiles of paired tumors from patients with TNBC. Experimental Design: We collected paired primary and metastatic TNBC specimens from 43 patients and performed targeted exome sequencing and whole-transcriptome sequencing. From these efforts, we ascertained somatic mutation profiles, tumor mutational burden (TMB), TNBC molecular subtypes, and immune-related gene expression patterns. Stromal tumor-infiltrating lymphocytes (stromal TIL), recurrence-free survival, and overall survival were also analyzed. Results: We observed a typical TNBC mutational landscape with minimal shifts in copy number or TMB over time. However, there were notable TNBC molecular subtype shifts, including increases in the Lehmann/Pietenpol-defined basal-like 1 (BL1, 11.4%–22.6%) and mesenchymal (M, 11.4%–22.6%) phenotypes, and a decrease in the immunomodulatory phenotype (IM, 31.4%–3.2%). The Burstein-defined basal-like immune-activated phenotype was also decreased (BLIA, 42.2%–17.2%). Among downregulated genes from metastases, we saw enrichment of immune-related Kyoto Encyclopedia of Genes and Genomes pathways and gene ontology (GO) terms, and decreased expression of immunomodulatory gene signatures (P &amp;lt; 0.03) and percent stromal TILs (P = 0.03). There was no clear association between stromal TILs and survival. Conclusions: We observed few mutational shifts, but largely consistent transcriptomic shifts in longitudinally paired TNBCs. Transcriptomic and IHC analyses revealed significantly reduced immune-activating gene expression signatures and TILs in recurrent TNBCs. These data may explain the observed lack of efficacy of immunotherapeutic agents in heavily pretreated TNBCs. Further studies are ongoing to better understand these initial observations. See related commentary by Savas and Loi, p. 526
Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation
Authors: Benedetto Bruno, Paola Omedè, Silvia Cena, Maddalena Noviello, Milena Gilestro, Laura Cimolin, Silvia Mattia, Cristian Sfiligoi, Elisa Galletto, Luciana Veneziano, Luisa Giaccone, Roberto Sorasio, Moreno Festuccia, Federica Ferrando, Lucia Brunello, Massimo Massaia, Alessandro Aiuti, Chiara Bonini, Roberto Passera, Franca Fagioli, Mario Boccadoro
Journal: Blood (2010)
Relief of tumor hypoxia unleashes the tumoricidal potential of neutrophils
Authors: Karim Mahiddine, Adam Blaisdell, Stephany Ma, Amandine Créquer-Grandhomme, Clifford A. Lowell, Adrian Erlebacher
Journal: Journal of Clinical Investigation (2019)

Polymorphonuclear neutrophils (PMNs) are increasingly recognized to influence solid tumor development, but why their effects are so context dependent and even frequently divergent remains poorly understood. Using an autochthonous mouse model of uterine cancer and the administration of respiratory hyperoxia as a means to improve tumor oxygenation, we provide in vivo evidence that hypoxia is a potent determinant of tumor-associated PMN phenotypes and direct PMN-tumor cell interactions. Upon relief of tumor hypoxia, PMNs were recruited less intensely to the tumor-bearing uterus, but the recruited cells much more effectively killed tumor cells, an activity our data moreover suggested was mediated via their production of NADPH oxidase-derived reactive oxygen species and MMP-9. Simultaneously, their ability to promote tumor cell proliferation, which appeared to be mediated via their production of neutrophil elastase, was rendered less effective. Relieving tumor hypoxia thus greatly improved net PMN-dependent tumor control, leading to a massive reduction in tumor burden. Remarkably, this outcome was T cell independent. Together, these findings identify key hypoxia-regulated molecular mechanisms through which PMNs directly induce tumor cell death and proliferation in vivo and suggest that the contrasting properties of PMNs in different tumor settings may in part reflect the effects of hypoxia on direct PMN-tumor cell interactions.
Impact of Somatic Mutations on Outcome in Patients with MDS after Stem-Cell Transplantation
Authors: Tetsuichi Yoshizato, Yusuke Shiozawa, Kenichi Yoshida, Yoshiko Atsuta, Chika Ito, Keisuke Kataoka, Makoto Onizuka, Hiromichi Suzuki, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Yasunobu Nagata, Masashi Sanada, Hidehiro Itonaga, Yoshinobu Kanda, Yasushi Miyazaki, Hideki Makishima, Satoru Miyano, Seishi Ogawa
Journal: Blood (2015)
A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4+Foxp3+ Regulatory T Cells in Murine Models
Authors: Omar Duramad, Amy Laysang, Jun Li, Natalie Nguyen, Yasuyuki Ishii, Reiko Namikawa
Journal: Blood (2008)
Protective, Antigen-Specific Immunity in Children Treated for ALL Is Due to Selective Preservation of T-Cell Memory.
Authors: W. Nicholas Haining, D. Neuberg, H. Keczkemethy, J. Evans, S. Rivoli, J. Guenaga, D. Douek, S. Sallan, E. Guinan, L. Nadler
Journal: Blood (2004)
Epitope Specific Discrepancies Between Antibody Mediated Inhibition Of Recombinant Factor VIII and Plasma Derived Factor VIII Containing Von Willebrand Factor Affecting All Domains Of Factor VIII
Authors: Tami Livnat, Amy L. Dunn, Shirley Azar-Avivi, Wallace Hunter Baldwin, Gili Kenet, Shannon L. Meeks
Journal: Blood (2013)
Leukemia Driven By a NUP98-Phd Domain Fusion Is Highly Sensitive To Disruption Of H3K4me3-Phd Domain Binding By a Small Molecule Inhibitor
Authors: Sheryl M Gough, Fan Lee, Robert L Walker, Fan Yang, Yuelin Zhu, Marbin Pineda, Masahiro Onozawa, Yang Jo Chung, Sven Bilke, Elise K Wagner, John M Denu, Yi Ning, Paul S Meltzer, Peter D Aplan
Journal: Blood (2013)
Gemtuzumab Ozogamicin After Allogeneic Stem Cell Transplantation for Acute Leukemia
Authors: Takeshi Kobayashi, Naoki Shingai, Shuntaro Ikegawa, Yukie Takahashi, Jun Aoki, Kosuke Yoshioka, Jinichi Mori, Megumi Yasunaga, Yoshio Umezawa, Gaku Oshikawa, Noriko Doki, Kazuhiko Kakihana, Kazuteru Ohashi, Hisashi Sakamaki
Journal: Blood (2012)
Incidence and Predictors of Late-Occurring Central Nervous System Complications in Allogeneic Hematopoietic Cell Transplant Survivors
Authors: Aida Siyahian, Heeyoung Kim, Jennifer Berano Teh, Howard Chang, Liezl Atencio, Alicia Gonzales, F. Lennie Wong, Ryotaro Nakamura, Canlan Sun, Saro Armenian
Journal: Blood (2016)